



Provincial Health Services Authority

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca/terms-of-use and according to acceptable standards of care.

PROTOCOL CODE: LUNAPPPMB Neoadjuvant Phase

(Page 1 of 3)

DOCTOR'S ORDERS		Ht _____ cm Wt _____ kg BSA _____ m ²
REMINDER: Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form		
DATE:	To be given:	Cycle #:
Date of Previous Cycle: _____		
<input type="checkbox"/> Delay treatment _____ week(s) <input type="checkbox"/> CBC & Diff day of treatment		
May proceed with pemetrexed, CISplatin, CARBOplatin as written if within 96 hours ANC greater than or equal to 1.5 x 10⁹/L, platelets greater than or equal to 100 x 10⁹/L, and creatinine clearance greater than or equal to 45 mL/minute (for pemetrexed and CARBOplatin), or greater than or equal to 60 mL/minute (for CISplatin)		
May proceed with pembrolizumab if within 96 hours creatinine less than or equal to 1.5 times the upper limit of normal and less than or equal to 1.5 times the baseline, ALT less than or equal to 3 times the upper limit of normal, total bilirubin less than or equal to 1.5 times the upper limit of normal		
Dose modification for: <input type="checkbox"/> Hematology <input type="checkbox"/> Other Toxicity: _____		
Proceed with treatment based on blood work from _____		
PREMEDICATIONS: Patient to take own supply. RN/Pharmacist to confirm _____.		
dexamethasone <input type="checkbox"/> 8 mg or <input type="checkbox"/> 12 mg (select one) PO 30 to 60 minutes prior to treatment		
AND select ONE of the following:	<input type="checkbox"/>	aprepitant 125 mg PO 30 to 60 minutes prior to treatment, and ondansetron 8 mg PO 30 to 60 minutes prior to treatment
	<input type="checkbox"/>	netupitant-palonosetron 300 mg-0.5 mg PO 30 to 60 minutes prior to treatment
	<input type="checkbox"/>	ondansetron 8 mg PO 30 to 60 minutes prior to treatment
If additional antiemetic required:		
<input type="checkbox"/> OLANzapine <input type="checkbox"/> 2.5 mg or <input type="checkbox"/> 5 mg or <input type="checkbox"/> 10 mg (select one) PO 30 to 60 minutes prior to treatment		
Ensure patient is taking folic acid and has had vitamin B12 injection starting at least 7 days prior to first cycle, and to continue while on treatment, until 21 days after last pemetrexed dose.		
For prior infusion reaction to pembrolizumab:		
<input type="checkbox"/> diphenhydrAMINE 50 mg PO 30 minutes prior to treatment		
<input type="checkbox"/> acetaminophen 325 to 975 mg PO 30 minutes prior to treatment		
<input type="checkbox"/> hydrocortisone 25 mg IV 30 minutes prior to treatment		
<input type="checkbox"/> Other:		
Have Hypersensitivity Reaction Tray & Protocol Available		
PREHYDRATION:		
1000 mL NS over 60 minutes prior to CISplatin		
Continued on page 2		
DOCTOR'S SIGNATURE:		SIGNATURE:
		UC:



Provincial Health Services Authority

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca/terms-of-use and according to acceptable standards of care.

PROTOCOL CODE: LUNAPPPMB

Neoadjuvant Phase

(Page 2 of 3)

DATE:

****Have Hypersensitivity Reaction Tray & Protocol Available****

TREATMENT:

pembrolizumab 2 mg/kg x _____ kg = _____ mg (max. 200 mg)

IV in 50 mL NS over 30 minutes using a 0.2 micron in-line filter (may be given during prehydration)

Pharmacist to select **dose band** per last page of PPO. Complete table below (please print)

Drug	Dose Band (mg)	Pharmacist Initial and Date
pembrolizumab		

pemetrexed 500 mg/m² x BSA = _____ mg

☐ Dose Modification: _____ % = _____ mg/m² x BSA = _____ mg

IV in 100 mL NS over 10 minutes (may be given during prehydration)

Select one:

☐ **CISplatin 75 mg/m² x BSA = _____ mg**

☐ Dose Modification: _____ % = _____ mg/m² x BSA = _____ mg

IV in 500 mL NS, with potassium chloride 20 mmol, magnesium sulphate 1 g and mannitol 30 g over 60 minutes

OR

☐ **CARBOplatin AUC 5 x (GFR + 25) = _____ mg IV in 100 to 250 mL NS over 30 minutes**

RETURN APPOINTMENT ORDERS

☐ Return in **three** weeks for Doctor and Cycle _____.

☐ Return in _____ week(s) for post-operative visit and Cycle 5 (adjuvant phase).

CBC & Diff, creatinine, alkaline phosphatase, ALT, total bilirubin, LDH, sodium, potassium, TSH prior to each treatment

If clinically indicated:

☐ **ECG** ☐ **chest x-ray**

☐ **serum HCG** or ☐ **urine HCG** (select one) – required for woman of childbearing potential

☐ **free T3 and free T4** ☐ **lipase** ☐ **morning serum cortisol** ☐ **serum ACTH levels**

☐ **testosterone** ☐ **estradiol** ☐ **FSH** ☐ **LH** ☐ **creatinine kinase** ☐ **random glucose**

☐ **Weekly nursing assessment for (specify concern):** _____

☐ **Consults:**

☐ **See general orders sheet for additional requests.**

DOCTOR'S SIGNATURE:

SIGNATURE:

UC:



Provincial Health Services Authority

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca/terms-of-use and according to acceptable standards of care.

PROTOCOL CODE: LUNAPPPMB

Neoadjuvant Phase

(Page 3 of 3)

PEMBROLIZUMAB DOSE BANDING TABLE (2 mg/kg capped 200 mg)

Ordered Dose (mg)		Rounded dose (mg)
From:	To:	
Less than 70		Pharmacy prepares specific dose
70	80.49	75
80.5	92.49	85
92.5	110.49	100
110.5	137.49	125
137.5	162.49	150
162.5	187.49	175
187.5	200	200